Marvin & Palmer Associates Inc. Invests $5.03 Million in Eli Lilly And Co (LLY) Stock

Share on StockTwits

Marvin & Palmer Associates Inc. acquired a new position in shares of Eli Lilly And Co (NYSE:LLY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 43,467 shares of the company’s stock, valued at approximately $5,030,000. Eli Lilly And Co accounts for approximately 4.3% of Marvin & Palmer Associates Inc.’s portfolio, making the stock its 9th largest position.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Eli Lilly And Co by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 74,132,985 shares of the company’s stock valued at $7,955,211,000 after purchasing an additional 511,752 shares during the last quarter. Vanguard Group Inc increased its stake in shares of Eli Lilly And Co by 0.7% in the 3rd quarter. Vanguard Group Inc now owns 74,132,985 shares of the company’s stock valued at $7,955,211,000 after purchasing an additional 511,752 shares during the last quarter. BlackRock Inc. increased its stake in shares of Eli Lilly And Co by 3.0% in the 4th quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock valued at $7,979,649,000 after purchasing an additional 2,030,845 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in shares of Eli Lilly And Co by 17,720.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock valued at $367,000 after purchasing an additional 42,182,367 shares during the last quarter. Finally, Capital International Investors increased its stake in shares of Eli Lilly And Co by 7.6% in the 3rd quarter. Capital International Investors now owns 10,237,075 shares of the company’s stock valued at $1,098,541,000 after purchasing an additional 722,431 shares during the last quarter. Hedge funds and other institutional investors own 77.00% of the company’s stock.

NYSE LLY opened at $124.31 on Thursday. The company has a debt-to-equity ratio of 1.07, a quick ratio of 1.38 and a current ratio of 1.73. Eli Lilly And Co has a twelve month low of $74.51 and a twelve month high of $130.51. The firm has a market cap of $127.87 billion, a P/E ratio of 22.40, a PEG ratio of 2.49 and a beta of 0.33.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The firm had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same period last year, the business earned $1.14 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. On average, analysts forecast that Eli Lilly And Co will post 5.62 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 8th. Investors of record on Friday, February 15th were issued a dividend of $0.645 per share. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date was Thursday, February 14th. This represents a $2.58 annualized dividend and a dividend yield of 2.08%. Eli Lilly And Co’s dividend payout ratio (DPR) is 46.49%.

In related news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $122.48, for a total transaction of $25,108,400.00. Following the sale, the insider now owns 117,641,684 shares of the company’s stock, valued at approximately $14,408,753,456.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $127.01, for a total value of $127,010.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 833,190 shares of company stock worth $102,388,102. 0.11% of the stock is currently owned by company insiders.

Several equities analysts have recently issued reports on the company. JPMorgan Chase & Co. assumed coverage on Eli Lilly And Co in a research note on Tuesday. They issued an “overweight” rating and a $140.00 price target on the stock. Citigroup set a $124.00 price target on Eli Lilly And Co and gave the company a “hold” rating in a research note on Tuesday, February 26th. UBS Group decreased their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating on the stock in a research note on Friday, February 8th. Cantor Fitzgerald reiterated a “buy” rating on shares of Eli Lilly And Co in a research note on Monday, February 4th. Finally, Barclays reiterated a “buy” rating and issued a $130.00 price target on shares of Eli Lilly And Co in a research note on Sunday, January 20th. Eleven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $113.06.

COPYRIGHT VIOLATION NOTICE: “Marvin & Palmer Associates Inc. Invests $5.03 Million in Eli Lilly And Co (LLY) Stock” was first posted by Highlight Press and is the sole property of of Highlight Press. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://highlightpress.com/2019/03/14/marvin-palmer-associates-inc-invests-5-03-million-in-eli-lilly-and-co-lly-stock.html.

About Eli Lilly And Co

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Story: Cost of equity and a company’s balance sheet

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply